Studying the Immune System's Role in Neuropsychiatric Symptoms
Looks for immune signs in blood of people with suspected immune-related neuropsychiatric symptoms.
Key facts
- Who runs it
- King's College London
- Where
- London, United KingdomSee the 2 sites
- Trial code
- Registry title
- Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases
- Status
- Not yet recruiting
- People taking part
- 300 people, planned
- Started
- 1 Oct 2026
- Expected to end
- 1 Oct 2036
- Type of study
- Observational, 2 groups
- Record updated
- 27 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 16-100 who have had neuropsychiatric symptoms in the last year, where the immune system may play a role. It also needs control participants without such symptoms.
- Age
- 16 to 100 years
- Sex
- All sexes can join.
- Disease stage
- Current or previous neuropsychiatric symptoms within the last year, with a suspected immune cause. Control participants have had no such symptoms in the last year.
- Earlier treatment
- For the optional lumbar puncture, no antiplatelet or anticoagulant treatment in the 14 days before the procedure.
Main reasons for not taking part
- Unacceptable risk of harm to the participant or study staff because of behavioural disturbance
- Cannot have blood tests
- For the optional lumbar puncture: spinal deformity, injury, disease or previous lower spinal surgery
- For the optional lumbar puncture: known or suspected clotting disorder or raised pressure in the head
- For the optional lumbar puncture: allergy to local anaesthetic, or a history of chronic or recurrent headaches
The registry criteria, word for word
Show all 17 criteriaShow less
Who can take part
- Participants with Neuropsychiatric symptoms
- Age 16-100
- Current or previous neuropsychiatric symptoms within the last year
- Suspicion of immunological contribution to the aetiology of their neuropsychiatric symptoms; Control Participants
- Age 16-100
- No current or previous self-report of neuropsychiatric symptoms within the last year; Optional Lumbar Puncture only:
- Documented full blood count within the last 3 months with no clinically significant abnormalities
Who cannot take part
- Significant lower spinal deformity (such as spina bifida), injury, or disease (such as stenosis) or previous lower spinal surgery
- Antiplatelet or anticoagulant therapy within the 14 days prior to Lumbar Puncture procedure
- Known or suspected clotting disorder
- Known or suspected allergy to local anaesthetic agent or an ingredient of the anaesthetic solution
- History of chronic or recurrent headaches, in the opinion of the investigator
- Clinically significant abnormality in full blood count
- All Participants:
- Unacceptable risk of harm to participant or study staff due to risk of behavioural disturbance
- Inability to have blood tests; Optional Lumbar Puncture only:
- Known or suspected raised intracranial pressure, assessed by study clinician
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 100 years old?
Where in United Kingdom
- King's College HospitalLondon, United KingdomNot yet recruiting
- South London and Maudsley NHS Foundation TrustLondon, United KingdomNot yet recruiting
About the trial
What the trial wants to find out
The goal of this observational cohort study is to investigate the role of immune system in neuropsychiatric symptoms (NPS) and to identify immunological biomarkers that may improve the diagnosis, prognosis, and future treatment of immune-related neuropsychiatric disorders in individuals aged 16-100 years with suspected immune-mediated neuropsychiatric symptoms and matched control participants without neuropsychiatric symptoms.
Read full original descriptionShow less
The main questions it aims to answer are what immunological mechanisms are associated with neuropsychiatric symptoms across a range of neurological, psychiatric, autoimmune, infectious, and inflammatory conditions. Also, if immunological biomarkers can be identified that may support the diagnosis, prognosis, and future treatment of neuropsychiatric disorders in which the immune system may play a role.
Participants will provide a blood sample for immunological analysis and may optionally provide a cerebrospinal fluid (CSF) sample if a suitable previously collected sample is not available. Researchers may also analyse existing clinical and biological samples where available. Participants will provide demographic and clinical information, allow access to relevant medical record data, and may optionally provide additional blood samples, up to four times within one year, for further biomarker and immunological analyses.
The 2 groups in the trial
- Participants with neuropsychiatric symptoms
- Control Participants
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Dissecting Immunological and Autoimmune Mechanisms of Neuropsychiatric Diseases
- Plain-language title
- Studying the Immune System's Role in Neuropsychiatric SymptomsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07791212, who can take part
- Record updated
- 27 August 2026